{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T12:57:12Z","timestamp":1762865832391,"version":"build-2065373602"},"reference-count":59,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,7,22]],"date-time":"2013-07-22T00:00:00Z","timestamp":1374451200000},"content-version":"vor","delay-in-days":660,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brain, Behavior, and Immunity"],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1016\/j.bbi.2011.06.001","type":"journal-article","created":{"date-parts":[[2011,6,24]],"date-time":"2011-06-24T15:16:05Z","timestamp":1308928565000},"page":"1491-1497","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Lack of association of indoleamine 2,3-dioxygenase polymorphisms with interferon-alpha-related depression in hepatitis C"],"prefix":"10.1016","volume":"25","author":[{"given":"Amanda","family":"Galv\u00e3o-de Almeida","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucas C.","family":"Quarantini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aline S.","family":"Sampaio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9 C.","family":"Lyra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen L\u00edvia","family":"Parise","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymundo","family":"Paran\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irismar R.","family":"de Oliveira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karestan C.","family":"Koenen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c2ngela","family":"Miranda-Scippa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camila","family":"Guindalini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"1994","series-title":"Diagnostical and Statistical Manual of Mental Disorders","key":"10.1016\/j.bbi.2011.06.001_b0005"},{"key":"10.1016\/j.bbi.2011.06.001_b0010","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1590\/S1516-44462000000300003","article-title":"Mini International Neuropsychiatric Interview (MINI): valida\u00e7\u00e3o de entrevista breve para diagn\u00f3stico de transtornos mentais","volume":"22","author":"Amorim","year":"2000","journal-title":"Rev. Bras. Psiquiatr."},{"key":"10.1016\/j.bbi.2011.06.001_b0015","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1097\/FPC.0b013e32832c005a","article-title":"Identification of genetic variants in the human indoleamine 2, 3-dioxygenase (IDO1) gene, which have altered enzyme activity","volume":"19","author":"Arefayene","year":"2009","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/j.bbi.2011.06.001_b0020","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/01.mcg.0000210099.36500.fe","article-title":"Interferon-induced depression in chronic hepatitis C: a review of its prevalence, risk factors, biology, and treatment approaches","volume":"40","author":"Asnis","year":"2006","journal-title":"J. Clin. Gastroenterol."},{"key":"10.1016\/j.bbi.2011.06.001_b0025","first-page":"29","article-title":"IFN-induced depression: a role for NSAIDs","volume":"37","author":"Asnis","year":"2003","journal-title":"Psychopharmacol. Bull."},{"key":"10.1016\/j.bbi.2011.06.001_b0030","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.genhosppsych.2007.08.014","article-title":"High frequency of unrecognized mental disorders in HCV-infected patients","volume":"30","author":"Batista-Neves","year":"2008","journal-title":"Gen. Hosp. Psychiatry"},{"key":"10.1016\/j.bbi.2011.06.001_b0035","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1590\/S1413-86702009000100009","article-title":"Impact of psychiatric disorders on the quality of life of brazilian HCV-infected patients","volume":"13","author":"Batista-Neves","year":"2009","journal-title":"Braz. J. Infect. Dis."},{"key":"10.1016\/j.bbi.2011.06.001_b0040","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1001\/archpsyc.1961.01710120031004","article-title":"An inventory for measuring depression","volume":"4","author":"Beck","year":"1961","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.bbi.2011.06.001_b0045","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/hep.510240201","article-title":"An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group","volume":"24","author":"Bedossa","year":"1996","journal-title":"Hepatology"},{"key":"10.1016\/j.bbi.2011.06.001_b0050","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/00004714-200202000-00014","article-title":"Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system","volume":"22","author":"Bonaccorso","year":"2002","journal-title":"J. Clin. Psychopharmocol."},{"key":"10.1016\/j.bbi.2011.06.001_b0055","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0165-1781(01)00315-8","article-title":"Immunotherapy with interferon-alpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms","volume":"105","author":"Bonaccorso","year":"2001","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.bbi.2011.06.001_b0060","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1590\/S0034-89101995000500004","article-title":"Transtornos de humor em enfermarias de cl\u00ednica m\u00e9dica e valida\u00e7\u00e3o de escala de medida (HAD) de ansiedade e depress\u00e3o","volume":"29","author":"Botega","year":"1995","journal-title":"Rev. Sa\u00fade. P\u00fablica."},{"key":"10.1016\/j.bbi.2011.06.001_b0065","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1038\/mp.2008.48","article-title":"Functional polymorphisms in the interleukin-6 and serotonin transporter genes, and depression and fatigue induced by interferon-alpha and ribavirin treatment","volume":"14","author":"Bull","year":"2009","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.bbi.2011.06.001_b0070","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S0893-133X(01)00407-9","article-title":"Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions","volume":"26","author":"Capuron","year":"2002","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bbi.2011.06.001_b0075","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.biopsych.2004.02.009","article-title":"Cytokines and psychopathology: lessons from interferon-alpha","volume":"56","author":"Capuron","year":"2004","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.bbi.2011.06.001_b0080","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1056\/NEJM199904293401716","article-title":"Prediction of the depressive effects of interferon alfa therapy by the patient\u2019s initial affective state","volume":"340","author":"Capuron","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbi.2011.06.001_b0085","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s12640-009-9129-7","article-title":"The kynurenine pathway and inflammation in amyotrophic lateral sclerosis","volume":"18","author":"Chen","year":"2010","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.bbi.2011.06.001_b0090","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.phrs.2010.10.009","article-title":"Effects of PEG-interferon alpha plus ribavirin on tryptophan metabolism in patients with chronic hepatitis C","volume":"63","author":"Comai","year":"2011","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bbi.2011.06.001_b0095","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1038\/ng1669","article-title":"Efficiency and power in genetic association studies","volume":"37","author":"De Bakker","year":"2005","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bbi.2011.06.001_b0100","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1176\/appi.psy.44.2.104","article-title":"A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C","volume":"44","author":"Dieperink","year":"2003","journal-title":"Psychosomatics"},{"key":"10.1016\/j.bbi.2011.06.001_b0105","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.genhosppsych.2010.03.001","article-title":"Can antidepressants prevent interferon-alpha-induced depression? A review of the literature","volume":"32","author":"Galv\u00e3o-de Almeida","year":"2010","journal-title":"Gen. Hosp. Psychiatry"},{"key":"10.1016\/j.bbi.2011.06.001_b0110","doi-asserted-by":"crossref","first-page":"914","DOI":"10.3109\/15622975.2010.504282","article-title":"Is the interferon-\u03b1-triggered depressive episode a self-limited kind of depression? Four cases of persistent affective symptoms after antiviral treatment in HCV-infected individuals","volume":"11","author":"Galv\u00e3o-de Almeida","year":"2010","journal-title":"World J. Biol. Psychiatry"},{"key":"10.1016\/j.bbi.2011.06.001_b0115","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1007\/s10620-006-9729-5","article-title":"Preventing relapse of major depression during interferon-alpha therapy for hepatitis C\u2014A pilot study","volume":"52","author":"Gleason","year":"2007","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.bbi.2011.06.001_b0120","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/(SICI)1520-6394(1996)4:4<160::AID-DA2>3.0.CO;2-J","article-title":"Comorbid depression and anxiety spectrum disorders","volume":"4","author":"Gorman","year":"1996","journal-title":"Depress Anxiety"},{"key":"10.1016\/j.bbi.2011.06.001_b0125","doi-asserted-by":"crossref","first-page":"4552","DOI":"10.1073\/pnas.0504789103","article-title":"A dopamine transporter gene functional variant associated with cocaine abuse in a Brazilian sample","volume":"103","author":"Guindalini","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbi.2011.06.001_b0130","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/sj.mp.4001119","article-title":"A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C","volume":"7","author":"Hauser","year":"2002","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.bbi.2011.06.001_b0135","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1176\/appi.psy.41.5.439","article-title":"Prophylactic treatment of depression induced by interferon-alpha","volume":"41","author":"Hauser","year":"2000","journal-title":"Psychosomatics"},{"key":"10.1016\/j.bbi.2011.06.001_b0140","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S0163-8343(02)00239-6","article-title":"Incidence and clinical course of major depression in patients with chronic hepatitis type C undergoing interferon-alpha therapy: a prospective study","volume":"25","author":"Horikawa","year":"2003","journal-title":"Gen. Hosp. Psychiatry"},{"key":"10.1016\/j.bbi.2011.06.001_b0145","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s11920-007-0028-4","article-title":"Interferon-induced depression in hepatitis C: an update","volume":"9","author":"Keefe","year":"2007","journal-title":"Curr. Psychiatry Rep."},{"key":"10.1016\/j.bbi.2011.06.001_b0150","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1053\/j.gastro.2007.02.053","article-title":"Serotonin-1A receptor gene HTR1A variation predicts interferon-induced depression in chronic hepatitis C","volume":"132","author":"Kraus","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bbi.2011.06.001_b0155","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/j.1365-2893.2005.00554.x","article-title":"Prophylactic SSRI during interferon alpha re-therapy in patients with chronic hepatitis C and a history of interferon-induced depression","volume":"12","author":"Kraus","year":"2005","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.bbi.2011.06.001_b0160","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/j.1478-3231.2008.01934.x","article-title":"The global burden of hepatitis C","volume":"29","author":"Lavanchy","year":"2009","journal-title":"Liver Int."},{"key":"10.1016\/j.bbi.2011.06.001_b0165","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/hep.23699","article-title":"Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C","volume":"52","author":"Leutscher","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.bbi.2011.06.001_b0170","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.biopsych.2008.08.009","article-title":"Risk for depression during interferon-alpha treatment is affected by the serotonin transporter polymorphism","volume":"65","author":"Lotrich","year":"2009","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.bbi.2011.06.001_b0175","article-title":"IL28B polymorphism is associated with both side effects and clearance of hepatitis C during interferon-alpha therapy","author":"Lotrich","year":"2010","journal-title":"J. Interferon Cytokine Res."},{"key":"10.1016\/j.bbi.2011.06.001_b0180","article-title":"Depression is an inflammatory disease, but cell-mediated immune activation is the key component of depression","author":"Maes","year":"2010","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.bbi.2011.06.001_b0185","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1093\/nar\/16.3.1215","article-title":"A simple salting out procedure for extracting DNA from human nucleated cells","volume":"16","author":"Miller","year":"1988","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bbi.2011.06.001_b0190","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jad.2007.01.007","article-title":"A randomized trial of paroxetine to prevent interferon-alpha-induced depression in patients with hepatitis C","volume":"103","author":"Morasco","year":"2007","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.bbi.2011.06.001_b0195","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1056\/NEJM200103293441303","article-title":"Paroxetine for the prevention of depression induced by high-dose interferon alfa","volume":"344","author":"Musselman","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbi.2011.06.001_b0200","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1101\/gr.157901","article-title":"High-throughput SNP genotyping by allele-specific PCR with universal energy-transfer-labeled primers","volume":"11","author":"Myakishev","year":"2001","journal-title":"Genome Res."},{"key":"10.1016\/j.bbi.2011.06.001_b0205","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S0006-3223(02)01677-3","article-title":"The identification of OCD-related subgroups based on comorbidity","volume":"53","author":"Nestadt","year":"2003","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.bbi.2011.06.001_b0210","first-page":"101","article-title":"Depression during interferon therapy in chronic hepatitis C patients","volume":"99","author":"Otsubo","year":"1997","journal-title":"Seishin Shinkeigaku Zasshi"},{"key":"10.1016\/j.bbi.2011.06.001_b0215","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1111\/j.1572-0241.1999.00857.x","article-title":"Intravenous vitamin complexes used in sporting activities and transmission of HCV in Brazil","volume":"94","author":"Parana","year":"1999","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.bbi.2011.06.001_b0220","first-page":"137","article-title":"A functional serotonin transporter gene polymorphism and depressive effects associated with interferon-alpha treatment","volume":"51","author":"Pierucci-Lagha","year":"2010","journal-title":"Psychosomatics"},{"key":"10.1016\/j.bbi.2011.06.001_b0225","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1093\/genetics\/155.2.945","article-title":"Inference of population structure using multilocus genotype data","volume":"155","author":"Pritchard","year":"2000","journal-title":"Genetics"},{"key":"10.1016\/j.bbi.2011.06.001_b0230","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1111\/j.1478-3231.2007.01532.x","article-title":"Incidence of psychiatric side effects during pegylated interferon-alpha retreatment in nonresponder hepatitis C virus-infected patients","volume":"27","author":"Quarantini","year":"2007","journal-title":"Liver Int."},{"key":"10.1016\/j.bbi.2011.06.001_b0235","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1002\/jmv.21508","article-title":"A neuropsychological study comparing patients infected with HCV and HBV without psychiatric comorbidities","volume":"81","author":"Quarantini","year":"2009","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.bbi.2011.06.001_b0240","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/01.WNF.0000220824.57769.E5","article-title":"Effect of amantadine on depressive symptoms in chronic hepatitis C patients treated with pegylated interferon: a randomized, controlled pilot study","volume":"29","author":"Quarantini","year":"2006","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.bbi.2011.06.001_b0245","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2165\/00023210-200519020-00002","article-title":"Neuropsychiatric adverse effects of interferon-alpha: recognition and management","volume":"19","author":"Raison","year":"2005","journal-title":"CNS Drugs"},{"key":"10.1016\/j.bbi.2011.06.001_b0250","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1111\/j.1365-2036.2007.03316.x","article-title":"Paroxetine for prevention of depressive symptoms induced by interferon-alpha and ribavirin for hepatitis C","volume":"25","author":"Raison","year":"2007","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.bbi.2011.06.001_b0255","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S0278-5846(01)00324-4","article-title":"Interferon alpha (IFN-alpha) and psychiatric syndromes: a review","volume":"26","author":"Schaefer","year":"2002","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.bbi.2011.06.001_b0260","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2005.01.020","article-title":"Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C","volume":"42","author":"Schaefer","year":"2005","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bbi.2011.06.001_b0265","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/1479-7364-2-2-81","article-title":"Large-scale SNP analysis reveals clustered and continuous patterns of human genetic variation","volume":"2","author":"Shriver","year":"2005","journal-title":"Hum. Genomics"},{"key":"10.1016\/j.bbi.2011.06.001_b0270","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.biopsych.2009.11.005","article-title":"Phospholipase A2 and cyclooxygenase 2 genes influence the risk of interferon-alpha-induced depression by regulating polyunsaturated fatty acids levels","volume":"67","author":"Su","year":"2010","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.bbi.2011.06.001_b0275","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/nature02168","article-title":"The International HapMap Project","volume":"426","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.bbi.2011.06.001_b0280","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0013-7006(05)82400-5","article-title":"Hepatitis C, interferon \u03b1 and depression: main physiopathologic hypothesis","volume":"31","author":"Vignau","year":"2005","journal-title":"Encephale"},{"key":"10.1016\/j.bbi.2011.06.001_b0285","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1017\/S1461145702003103","article-title":"The psychoneuroimmuno-pathophysiology of cytokine induced depression in humans","volume":"5","author":"Wichers","year":"2002","journal-title":"Int. J. Neuropsychopharmacol."},{"year":"1991","series-title":"International Classification of Diseases (ICD-10)","author":"Organization","key":"10.1016\/j.bbi.2011.06.001_b0290"},{"key":"10.1016\/j.bbi.2011.06.001_b0295","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1159\/000086605","article-title":"Promoter polymorphisms of the interferon-alpha receptor gene and development of Interferon-induced depressive symptoms in patients with chronic hepatitis C: preliminary findings","volume":"52","author":"Yoshida","year":"2005","journal-title":"Neuropsychobiology"}],"container-title":["Brain, Behavior, and Immunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S088915911100198X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S088915911100198X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:29:35Z","timestamp":1760167775000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S088915911100198X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":59,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["S088915911100198X"],"URL":"https:\/\/doi.org\/10.1016\/j.bbi.2011.06.001","relation":{},"ISSN":["0889-1591"],"issn-type":[{"type":"print","value":"0889-1591"}],"subject":[],"published":{"date-parts":[[2011,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lack of association of indoleamine 2,3-dioxygenase polymorphisms with interferon-alpha-related depression in hepatitis C","name":"articletitle","label":"Article Title"},{"value":"Brain, Behavior, and Immunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbi.2011.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}